Skip to main content

Jefferies Sticks to Their Buy Rating for Lantheus (LNTH)

Tipranks - Tipranks - Sat Feb 28, 11:00AM CST

Jefferies analyst Matthew Taylor maintained a Buy rating on Lantheus today and set a price target of $105.00.

Claim 50% Off TipRanks Premium

Taylor covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, GE Healthcare Technologies Inc, and Abbott Laboratories. According to TipRanks, Taylor has an average return of 8.6% and a 56.33% success rate on recommended stocks.

In addition to Jefferies, Lantheus also received a Buy from Truist Financial’s Richard Newitter in a report issued today. However, yesterday, TipRanks – Google downgraded Lantheus (NASDAQ: LNTH) to a Hold.

See the top stocks recommended by analysts >>

Based on Lantheus’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $406.79 million and a net profit of $54.09 million. In comparison, last year the company earned a revenue of $391.11 million and had a GAAP net loss of $11.79 million

Read More on LNTH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).